细胞计数市场 - 全球产业规模、份额、趋势、机会及预测（按产品、应用、最终用途、地区和竞争格局划分，2021-2031年）

全球细胞计数市场预计将从 2025 年的 103.6 亿美元成长到 2031 年的 163.9 亿美元，复合年增长率为 7.95%。

此领域透过对生物样本中的细胞进行定量分析，辅助医学诊断、生物过程控制和药物研发。推动市场发展的关键因素是全球慢性病发病率的上升以及生物製药研发的成长，这两者都需要严谨的细胞学分析。美国癌症协会的数据凸显了这一临床需求，该协会预测，到2025年，美国将新增2,041,910例癌症病例，这强调了精准细胞评估工具对于辅助准确诊断和治疗方案製定的迫切需求。

儘管自动化设备具有良好的成长前景，但其高昂的实施和维修成本构成了市场推广的一大障碍。现代流式细胞仪和数位计数器所需的大量资本投入，使得预算有限的学术机构和小规模实验室难以采用这些设备。因此，这些经济障碍迫使资源有限的机构依赖人工计数方法，阻碍了自动化技术在对成本敏感的区域市场的广泛应用。

市场驱动因素

生物技术和生物製药研发的快速成长正成为市场的主要催化剂，催生了对先进测量设备的需求，以支持製程开发和药物发现。随着各机构加强对新型生物製药的研发力度，对细胞浓度和活力进行精确分析的需求至关重要，以确保符合监管要求和实验可重复性。研发投入的成长趋势十分显着。根据欧洲製药工业协会联合会 (EFPIA) 于 2024 年 6 月发布的《製药业数据概览》，2023 年欧洲製药业的研发支出将达到 500 亿欧元。这项巨额投资正推动自动化计数系统的采购，以应对临床和临床前试验中日益增多的细胞分析需求。

同时，再生医学和细胞疗法日益增长的需求正在从根本上改变市场格局。严格的品管通讯协定对于包括CAR-T疗法在内的细胞治疗药物的生产至关重要，而精确的细胞计数对于患者用药剂量和产品疗效评估至关重要。该领域的商业规模在大型生产合约中可见一斑。例如，三星生物製剂在2024年7月的新闻稿中宣布，已与一家美国製药公司签订了一份价值10.6亿美元的合同，用于扩大原料药（API）的生产能力。此外，对该治疗领域的投资依然强劲，推动了高通量计数解决方案的应用。根据再生医学联盟在2024年1月发布的「产业现况」报告，预计到2023年，全球细胞和基因治疗领域将吸引117亿美元的投资，这将确保对分析工具的持续需求。

市场挑战

引入自动化细胞计数器需要大量的资金投入，这成为市场扩张的主要障碍。高端流式细胞仪和数位影像分析仪的购置成本高昂，对于采购预算有限的学术研究机构和中小型受託研究机构（CRO）而言，难以负担。除了初始购置成本外，持续的营运成本，例如维护合约和专用试剂，也进一步抑制了对成本敏感的细分市场的潜在采购。因此，这些资金限制迫使许多资源有限的机构依赖人工计数技术，从而限制了自动化解决方案的潜在市场规模，并阻碍了收入成长。

科研经费停滞不前进一步加剧了这项经济负担，直接影响了科学界购置设备的能力。据美国实验生物学会联合会（FASEB）称，美国国立卫生研究院（NIH）2024财年的联邦预算约为471亿美元，这一增长幅度不大，远未跟上生物医学领域的通货膨胀速度。资金成长乏力限制了研究机构对资本密集技术的投资能力，并直接阻碍了现代细胞计数系统的广泛应用。

市场趋势

人工智慧 (AI) 和机器学习演算法的融合从根本上重新定义了细胞计数技术，实现了对复杂细胞形态的快速、无标记分析。这些先进的计算工具使研究人员能够克服传统染色技术的局限性，并在不损害细胞活性的前提下，即时精确地表征细胞状态。这种技术变革正日益被应用于高价值的治疗工作流程中，在这些流程中，维持细胞完整性至关重要。例如，2025 年 9 月发布的题为「Deepcell 和 InGel Therapeutics 宣布建立策略合作伙伴关係」的新闻稿指出，Deepcell 已与 InGel Therapeutics 合作，利用 InGel Therapeutics 的 AI 驱动的 REM-I 平台对视网膜细胞进行高维、无标定分析，以加速新型眼科治疗方法的研发。

同时，随着产业向更贴近生理实际的疾病模型转型，针对类器官和3D细胞培养的专用计数解决方案的开发也日益加速。与单层培养不同， 3D模型需要高度标准化的分析通讯协定，以确保毒性测试和药物筛检应用中的可重复性。联邦政府为推动类器官生产的产业化提供了重要支持。例如，美国国立卫生研究院（NIH）于2025年9月授予了一份总额达8700万美元的合同，旨在促进「标准化类器官建模（SOM）中心」的建立，以开发扩充性且可重复的基于类器官的药物发现和研究工作流程。相关消息已在题为「标准化类器官建模中心减少对动物模型的依赖」的新闻稿中公布。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球细胞计数市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（仪器（光强度、流式细胞仪、血球计数器、自动细胞计数器、显微镜等）、耗材及配件（试剂、微孔盘等））
  • 依应用领域（全血球计数（自动化、手动）、干细胞研究、细胞疗法、生物生物製程、毒理学、其他）
  • 按最终用户划分（医院和诊断机构、实验室、研究机构和学术机构、製药和生物技术公司、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美细胞数市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章 欧洲细胞计数市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区细胞计数市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲细胞计数市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美细胞计数市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球细胞计数市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc
• Merck KGaA
• Agilent Technologies, Inc.
• PerkinElmer Health Sciences Inc
• Becton Dickinson & Co
• Danaher Corp
• Bio-Rad Laboratories Inc
• BioTek Instruments Inc
• GE Healthcare Inc
• deNovis Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cell Counting Market is projected to increase from a valuation of USD 10.36 Billion in 2025 to USD 16.39 Billion by 2031, expanding at a CAGR of 7.95%. This sector involves quantifying cells in biological samples to facilitate medical diagnostics, bioprocess control, and pharmaceutical research. The market is primarily propelled by the rising global burden of chronic diseases and the growth of biopharmaceutical research and development, both of which require strict cytological analysis. This clinical need is highlighted by data from the American Cancer Society, which estimates that 2,041,910 new cancer cases will occur in the United States in 2025, underscoring the urgent necessity for precise cellular evaluation tools to support accurate diagnosis and treatment planning.

Despite these favorable growth prospects, the market encounters a major obstacle due to the high acquisition and maintenance costs linked to automated instrumentation. The significant capital investment needed for modern flow cytometers and digital counters limits their availability for academic institutions and smaller laboratories with restricted budgets. Consequently, these financial barriers often force resource-constrained facilities to continue relying on manual counting methods, which hinders the widespread adoption of automated technologies in cost-sensitive regional markets.

Market Driver

The rapid growth of biotechnology and biopharmaceutical research and development acts as a major catalyst for the market, creating a need for advanced instrumentation to support process development and drug discovery. As organizations increase their efforts to create novel biologics, the demand for accurate analysis of cell concentration and viability becomes essential to guarantee regulatory compliance and experimental reproducibility. This rising trend in development spending is significant; the European Federation of Pharmaceutical Industries and Associations reported in "The Pharmaceutical Industry in Figures" in June 2024 that the pharmaceutical industry's R&D expenditure in Europe hit €50,000 million in 2023. Such substantial financial commitment drives the purchase of automated counting systems to manage the growing volume of cell-based assays needed during clinical and preclinical phases.

Simultaneously, the increasing demand for regenerative medicine and cell-based therapies is fundamentally transforming the market landscape. Producing CAR-T and other cellular therapeutics necessitates strict quality control protocols, where precise cell enumeration is vital for establishing patient dosing and assessing product potency. The commercial scale of this sector is evident in major manufacturing deals; for example, Samsung Biologics announced in a July 2024 press release that it secured a $1.06 billion contract with a U.S. pharmaceutical company to enhance drug substance manufacturing capabilities. Moreover, investment in this therapeutic area remains strong, fueling the adoption of high-throughput counting solutions; according to the Alliance for Regenerative Medicine's January 2024 "State of the Industry" presentation, the global cell and gene therapy sector drew $11.7 billion in investment capital throughout 2023, ensuring continued demand for analytical tools.

Market Challenge

The substantial capital expenditure required for automated cell counting instrumentation represents a primary hurdle to market expansion. High-end flow cytometers and digital image-based analyzers come with steep acquisition costs, making them financially out of reach for academic laboratories and smaller contract research organizations with limited procurement budgets. Beyond the initial purchase price, significant ongoing operational costs, such as maintenance contracts and specialized reagents, further discourage potential buyers in cost-sensitive segments. As a result, these financial limitations force many resource-constrained facilities to depend on manual counting techniques, thereby limiting the total addressable market for automated solutions and retarding revenue growth.

This economic strain is further aggravated by stagnant research funding, which directly dictates equipment purchasing power within the scientific community. According to the Federation of American Societies for Experimental Biology, the 2024 federal budget for the National Institutes of Health was finalized at approximately $47.1 billion, a minor increase that failed to keep up with biomedical inflation. This lack of robust funding growth restricts the ability of research institutions to invest in capital-intensive technologies, directly impeding the broader integration of modern cell counting systems.

Market Trends

The incorporation of artificial intelligence and machine learning algorithms is fundamentally redefining cell counting by facilitating the high-speed, label-free analysis of complex cellular morphologies. These sophisticated computational tools allow researchers to circumvent the limitations of traditional staining techniques, offering precise, real-time characterization of cell states without harming viability. This technological shift is increasingly utilized in high-value therapeutic workflows where preserving cell integrity is essential. For example, in the "Deepcell and InGel Therapeutics Announce Strategic Partnership" press release from September 2025, Deepcell partnered with InGel Therapeutics to utilize its AI-driven REM-I platform for the high-dimensional, label-free analysis of retinal cells to expedite the development of new ocular therapies.

Concurrently, the creation of specialized counting solutions for organoids and 3D cell cultures is gaining momentum as the industry shifts toward physiologically relevant disease models. Unlike monolayer cultures, 3D models demand advanced standardization and analysis protocols to ensure reproducibility in toxicology and drug screening applications. This transition is supported by significant federal initiatives aimed at industrializing organoid production; for instance, the National Institutes of Health awarded contracts totaling $87 million in September 2025, as noted in the "Standardized Organoid Modeling Center to Reduce Reliance on Animal Modeling" press release, to launch the Standardized Organoid Modeling (SOM) Center, which is designed to develop scalable, reproducible workflows for organoid-based drug discovery and research.

Key Market Players

• Thermo Fisher Scientific Inc
• Merck KGaA
• Agilent Technologies, Inc.
• PerkinElmer Health Sciences Inc
• Becton Dickinson & Co
• Danaher Corp
• Bio-Rad Laboratories Inc
• BioTek Instruments Inc
• GE Healthcare Inc
• deNovis Inc

Report Scope

In this report, the Global Cell Counting Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Counting Market, By Product

• Instruments (Spectrophotometers, Flow Cytometers, Hemocytometers, Automated cell counters, Microscopes, Others)
• Consumables & Accessories (Reagents, Microplates, Others)

Cell Counting Market, By Application

• Complete Blood Count (Automated, Manual)
• Stem Cell Research
• Cell Based Therapeutics
• Bioprocessing
• Toxicology
• Others

Cell Counting Market, By End-use

• Hospitals &Diagnostic Laboratories
• Research & Academic Institutes
• Pharmaceutical & Biotechnology Companies
• Others

Cell Counting Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Counting Market.

Available Customizations:

Global Cell Counting Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Counting Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments (Spectrophotometers, Flow Cytometers, Hemocytometers, Automated cell counters, Microscopes, Others), Consumables & Accessories (Reagents, Microplates, Others))
  • 5.2.2. By Application (Complete Blood Count (Automated, Manual), Stem Cell Research, Cell Based Therapeutics, Bioprocessing, Toxicology, Others)
  • 5.2.3. By End-use (Hospitals &Diagnostic Laboratories, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cell Counting Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End-use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Counting Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-use
  • 6.3.2. Canada Cell Counting Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-use
  • 6.3.3. Mexico Cell Counting Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-use

7. Europe Cell Counting Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End-use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Counting Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-use
  • 7.3.2. France Cell Counting Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-use
  • 7.3.3. United Kingdom Cell Counting Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-use
  • 7.3.4. Italy Cell Counting Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-use
  • 7.3.5. Spain Cell Counting Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-use

8. Asia Pacific Cell Counting Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End-use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Counting Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-use
  • 8.3.2. India Cell Counting Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-use
  • 8.3.3. Japan Cell Counting Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-use
  • 8.3.4. South Korea Cell Counting Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-use
  • 8.3.5. Australia Cell Counting Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-use

9. Middle East & Africa Cell Counting Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End-use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Counting Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-use
  • 9.3.2. UAE Cell Counting Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-use
  • 9.3.3. South Africa Cell Counting Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-use

10. South America Cell Counting Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End-use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Counting Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-use
  • 10.3.2. Colombia Cell Counting Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-use
  • 10.3.3. Argentina Cell Counting Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Counting Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Agilent Technologies, Inc.
• 15.4. PerkinElmer Health Sciences Inc
• 15.5. Becton Dickinson & Co
• 15.6. Danaher Corp
• 15.7. Bio-Rad Laboratories Inc
• 15.8. BioTek Instruments Inc
• 15.9. GE Healthcare Inc
• 15.10. deNovis Inc

16. Strategic Recommendations

17. About Us & Disclaimer